Life sciences company Thermo Fisher (NYSE: TMO) will be reporting results this Wednesday before the bell. Here’s what investors should know.

Thermo Fisher beat analysts’ revenue expectations last quarter, reporting revenues of $11.99 billion, up 10.5% year on year. It was a very strong quarter for the company, with an impressive beat of analysts’ organic revenue estimates and a beat of analysts’ EPS estimates.

Is Thermo Fisher a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Thermo Fisher’s revenue to grow 7.6% year on year, improving from the 4.9% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Thermo Fisher rarely misses Wall Street’s revenue estimates.

With Thermo Fisher being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unfold for life sciences tools & services stocks. However, investors in the segment have had steady hands going into earnings, with share prices flat over the last month. Thermo Fisher is up 2.9% during the same time .

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.